Biotron Ltd has released a press release.
Agreement with C14 Consulting Group
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Biotron
- $1.8M R&D Rebate Received
- BIT225-012 phase 2 covid-19 clinical trial
- BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives
- Positive outcomes in BIT225 phase 2 clinical trial in hiv
- Response to ASX Price Query
Later from Biotron
- Updated Appendix 4C
- Renounceable Rights Issue
- Prospectus
- Response to ASX Aware Query
- Supplementary Prospectus
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron